Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Jefferson Health Announces Major Layoffs Amid Financial Challenges

Jefferson Health, a prominent academic health system based in Philadelphia, has confirmed plans to lay off approximately 650 employees, representing about 1% of its 65,000-person workforce. This decision comes in the wake of significant financial challenges faced by the organization, including a nearly $200 million operating loss in the latest fiscal year.

NoahAI News10/17/2025

Praxis Precision Medicines Achieves Breakthrough in Essential Tremor Treatment

Praxis Precision Medicines has announced a significant milestone in the development of a novel treatment for essential tremor, marking a potential paradigm shift in the management of this common neurological disorder. The company's experimental drug, ulixacaltamide, has demonstrated positive results in two late-stage clinical trials, paving the way for a potential FDA approval application by early 2026.

NoahAI News10/17/2025

J&J's Tecvayli Shows Promise in Earlier Multiple Myeloma Treatment

Johnson & Johnson (J&J) has announced positive results from a Phase 3 trial testing its dual-targeting antibody drug Tecvayli in combination with Darzalex for earlier-line treatment of multiple myeloma. This development marks a potential advancement in the treatment landscape for this persistent blood cancer.

NoahAI News10/17/2025

Johnson & Johnson to Spin Off Orthopedics Business, Sharpening Focus on High-Growth Medtech Sectors

Johnson & Johnson (J&J) announced plans to spin out its orthopedics business into a standalone company, a move aimed at refocusing its medtech portfolio on higher-growth areas such as cardiovascular and robotic surgery. The spinoff, to be named DePuy Synthes, is expected to complete within 18 to 24 months and will create the largest orthopedics company in the medical device space.

NoahAI News10/17/2025

BD CFO Chris DelOrefice to Depart Amid Preliminary Q4 Results and Ongoing Restructuring

In a significant leadership change, BD (Becton, Dickinson and Company) announced that Chief Financial Officer Chris DelOrefice will be leaving the company on December 5, 2025, to pursue a new opportunity as CFO at Ulta Beauty. This departure comes as BD releases preliminary fourth-quarter results that fell short of Wall Street expectations and continues its strategic separation of key business units.

NoahAI News10/17/2025

Praxis Achieves Breakthrough in Essential Tremor Treatment with Phase 3 Success

Praxis Precision Medicines has announced positive results from its Essential3 phase 3 program for ulixacaltamide, a potential treatment for essential tremor (ET). The company's persistence in continuing the trials despite earlier setbacks has paid off, with two pivotal studies demonstrating statistically significant improvements in patients' daily activities.

NoahAI News10/17/2025

Kite Pharma Inks $1.6B Deal with China's Pregene for In Vivo CAR-T Development

Gilead Sciences' subsidiary Kite Pharma has announced a significant partnership with Chinese biotech Pregene Biopharma, marking another major investment in the burgeoning field of in vivo CAR-T therapy. The collaboration, valued at up to $1.64 billion, aims to accelerate the development of next-generation cell therapies and expand their accessibility to patients worldwide.

NoahAI News10/17/2025

Connected Technology Enhances Decentralized Clinical Studies and Patient Compliance

In a recent episode of BioSpace's industry podcast, experts discussed the growing importance of connected technology in decentralized clinical studies and its impact on patient compliance, data processing, and trust-building in the pharmaceutical sector.

NoahAI News10/16/2025

Sanofi Expands Autoimmune Portfolio with $500M EVOQ Partnership

Sanofi, a global pharmaceutical giant, has entered into a strategic alliance with Chicago-based EVOQ Therapeutics, marking another significant investment in the autoimmune disease space. The partnership, valued at up to $500 million, centers on EVOQ's proprietary NanoDisc technology, which aims to develop potentially curative treatments for autoimmune conditions.

NoahAI News10/16/2025

FDA's Orphan Drug Office Sees Leadership Change Amid Policy Shifts

Sandra Retzky, the director of the FDA's Office of Orphan Products Development, has left her position, marking another significant change in the agency's leadership. While an unnamed source confirmed to Endpoints News that Retzky has not been fired, her new role within the FDA remains unclear. This move comes at a crucial time for orphan drug policy and regulation.

NoahAI News10/16/2025

Veradermics Secures $150M Series C for Hair Regrowth Pill, Signaling Renewed Interest in Aesthetic Dermatology

Connecticut-based Veradermics has successfully raised $150 million in an oversubscribed Series C funding round, marking a significant milestone in the development of its novel hair regrowth treatment. The financing, led by SR One, will support the company's ongoing Phase III studies for its lead program VDPHL01, an extended-release oral formulation of minoxidil designed to treat pattern hair loss in both men and women.

NoahAI News10/16/2025

Novartis Advances IgAN Treatment Landscape with Positive Phase 3 Results for Fabhalta

Novartis has announced significant progress in the treatment of IgA nephropathy (IgAN), a rare kidney disease, with positive final results from its Phase 3 Applause-IgAN trial for Fabhalta. The study demonstrated that the complement factor B inhibitor can effectively slow kidney function decline and disease progression, positioning the drug for full FDA approval and reinforcing Novartis's strong presence in the IgAN market.

NoahAI News10/16/2025

«1...19 20 21...67 »